The University of Chicago Header Logo

Connection

Mark J. Ratain to Sulfonamides

This is a "connection" page, showing publications Mark J. Ratain has written about Sulfonamides.
Connection Strength

1.266
  1. Vemurafenib oral bioavailability: an insoluble problem. J Clin Pharmacol. 2014 Apr; 54(4):375-7.
    View in: PubMed
    Score: 0.416
  2. Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors. Clin Pharmacol Ther. 2018 06; 103(6):956-958.
    View in: PubMed
    Score: 0.134
  3. Obviating the Need for Serial Biopsies Through Random Assignment. J Clin Oncol. 2017 01 10; 35(2):260.
    View in: PubMed
    Score: 0.124
  4. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
    View in: PubMed
    Score: 0.109
  5. Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib. Clin Cancer Res. 2015 Jan 15; 21(2):365-72.
    View in: PubMed
    Score: 0.109
  6. Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res. 2013 Dec 01; 19(23):6430-7.
    View in: PubMed
    Score: 0.100
  7. Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013 Jul; 23(7):374-81.
    View in: PubMed
    Score: 0.099
  8. Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One. 2013; 8(1):e54522.
    View in: PubMed
    Score: 0.096
  9. Bar the windows but open the door to randomization. J Clin Oncol. 2010 Jul 01; 28(19):3104-6.
    View in: PubMed
    Score: 0.080
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.